The year of 2013 in cardiology has been eventful with significant advances described in many fields including cardiac pharmacology, coronary artery intervention, percutaneous aortic valve implantation, heart failure, and electrophysiology. Perhaps one of the most rapidly expanding areas is that of renal denervation therapy (RDT) for treatment of resistant hypertension.
Catheter-based radiofrequency ablation of the efferent and afferent sympathetic nerves which lie within and just beyond the adventitia of the renal arteries has been shown to be a highly effective treatment for resistant hypertension ( Fig. 1 ). Potential beneficial mechanisms include reduction in peripheral resistance, reduced renin release, favorable changes in water and salt handling, and reduction in whole-body sympathetic-nerve activity.
The first randomized trial, Symplicity HTN-2, assigned 106 patients with systolic blood pressure [160 mmHg (or [150 mmHg in type 2 diabetics) despite C3 anti-hypertensive drugs to RDT or to usual care [1] . RDT was performed using the single point electrode Simplicity catheter (Medtronic, MN, USA) advanced via the femoral artery into the renal artery. Up to six radiofrequency ablations (each for 2 min) (Fig. 4) . The second generation device has an ablation time of 90 s per set of four simultaneous ablations with two treatments typically performed per artery. Early results of this device in EnligHTN-III showed 26/9 mmHg reduction of office blood pressure at 3 months (n = 20) [5] . 
